SciTech Development, Inc. Announces Receipt of Drug Supply from National Cancer Institute (NCI)

DETROIT, 17 September 2024 /PRNewswire/ — SciTech Development, Inc., a clinical-stage biotechnology company focused on innovative cancer therapeutics, is pleased to announce that the National Cancer Institute (NCI), part of the National Institutes of Health, has provided the Company with an additional supply of fenretinide, a key active pharmaceutical ingredient in the Company's investigational drug and drug pipeline ST-001.

The provision of fenretinide by the NCI will enable SciTech to treat over 300 patients, both Phase 1a and 1b its ongoing clinical trials at six sites and expands its clinical studies. This shipment will help SciTech achieve important Phase 1 results such as determining optimal drug dosing and evaluating the safety and tolerability of ST-001 in patients with relapsed or refractory T-cell non-Hodgkin lymphoma. In addition, it will reduce development costs and accelerate the development timeline of ST-001. For more details on the trials and sites, please see: https://clinicaltrials.gov/study/NCT04234048.

“We are honored to receive this additional supply of fenretinide from the National Cancer Institute,” said Earle HolsappleCEO of SciTech Development. “The continued support from the NCI underscores the potential of ST-001 in a broad range of cancer types, including the first-line treatment of patients with T-cell lymphoma. This contribution allows us to continue to advance our clinical programs without delay and advance both Phase 1a and 1b This brings us one step closer to our goal of being able to offer patients with difficult-to-treat cancers a new treatment option.”

ST-001 is a patented aqueous suspension of nanoparticles containing fenretinide in specially formulated phospholipid bilayers designed to improve the drug's bioavailability, delivery and potential efficacy in cancer treatment. Fenretinide has been extensively studied and offers unique advantages such as multiple anti-cancer mechanisms of action, a favorable safety profile and its broad applicability to other cancer types.

SciTech Development is committed to bringing innovative therapies to patients and is grateful for the continued support of the NCI. The company looks forward to providing future updates on the progress of clinical trials.

For more information about SciTech Development and its clinical programs, visit www.SciTechSDP.com.

CONTACT:

David SchafferInvestor Relations

[email protected]

About SciTech Development, Inc.

SciTech Development, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for the treatment of cancer. SciTech is focused on advancing its clinical programs to bring innovative and effective cancer treatments to patients worldwide.

This press release may contain forward-looking statements that are subject to risks and uncertainties. These statements are based on current expectations and assumptions and are not guarantees of future performance.

View original content to download multimedia: